



Results of HIV Biologic and Long-Acting Investigational Antiretroviral Ibalizumab to be Presented in Late-Breaker Session at IDWeek 2016

October 28, 2016

Theratechnologies Inc. (Theratechnologies) (TSX: TH) announced additional results related to the primary endpoint of the ibalizumab Phase III pivotal study, TMB-301. The initial results were announced on May 24, 2016.